Comparing 177Lu-edotreotide Radiotherapy with Everolimus Treatment
for Advanced Somatostatin Receptor Positive Neuroendocrine Tumors
of the Lung and Thymus A Phase III Study
Led by Grupo Espanol de Tumores Neuroendocrinos · Updated on 2026-05-12
170
Participants Needed
27
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
This research trial investigates the treatment of well to moderately differentiated neuroendocrine tumors of the lung and thymus. It compares two therapies 177Lu-edotreotide, a type of peptide receptor radionuclide therapy, and everolimus, an oral drug. The study focuses on patients whose tumors have high expression of somatostatin receptors as confirmed by imaging and aims to determine which treatment better delays disease progression.
Participants will be randomly assigned in a 32 ratio to receive either 177Lu-edotreotide or everolimus. The 177Lu-edotreotide group will receive 6 cycles of treatment spaced between 6 to 8 weeks apart, while the everolimus group will take a daily oral dose of 10 mg until disease progression, intolerable side effects, or death. Treatment will continue unless stopped due to progression, toxicity, or patient choice.
Throughout the study, patients will undergo regular tumor assessments using MRI or CT scans every 12 weeks to monitor disease progression. Researchers will measure progression-free survival as the primary outcome over about three years per participant. Other assessments include tumor response rates, overall survival, and quality of life questionnaires. Safety and long-term follow-up will continue even if treatment stops, unless participants withdraw consent entirely.
CONDITIONS
Brief Title
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Research Team
F
Federico Nepote
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed metastatic or locally advanced unresectable well or moderately differentiated neuroendocrine tumor of lung (typical and atypical carcinoids) or thymus origin
Tumors must have high somatostatin receptor expression confirmed by PET imaging
Radiological evidence of disease progression within 12 months prior to study entry
Patients may be treatment-naive or have received up to two prior systemic anti-tumor therapies
Measurable metastatic or locally advanced disease at baseline by RECIST v1.1
Archival or new tumor tissue sample available for central laboratory analysis
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ and bone marrow function based on laboratory tests
Female participants must have a negative pregnancy test and agree to use effective contraception during and 6 months after treatment
Male participants must agree to use contraception or abstain if partner is pregnant or breastfeeding
Agreement not to participate in another interventional study during treatment
You will not qualify if you...
Unable to swallow tablets
Poorly differentiated or high-grade neuroendocrine carcinoma or mixed tumors
Brain metastases unless stable for more than 12 weeks without symptoms
Ongoing significant toxicity from prior treatments (grade 2 or higher except alopecia)
Recent diagnosis or active treatment for another malignancy within 12 months
Active infections such as hepatitis B, hepatitis C, or HIV
Live vaccine received within 4 weeks prior to treatment or planned during treatment and 3 months after
History of recent serious cardiovascular events within 6 months
Prior peptide receptor radionuclide therapy or mTOR inhibitor treatment
Recent radiotherapy or major surgery within 12 weeks prior to treatment
Chemotherapy, biologics, immunotherapy not completed at least 4 weeks prior to treatment
Known hypersensitivity to everolimus, 177Lu-edotreotide, or related substances
Other medical conditions that may prevent safe treatment or follow-up as judged by investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to approximately 3 years or until disease progression or intolerable toxicity
Participants receive either 6 cycles of 177Lu-edotreotide given every 6 to 8 weeks or daily oral everolimus until disease progression, intolerable toxicity, or death.
6 treatment cycles for 177Lu-edotreotide with visits approximately every 6 to 8 weeks or daily oral dosing for everolimus with regular visits
Follow-up
Duration - Up to approximately 3 years including long-term follow-up
Participants continue with scheduled assessments including tumor scans and quality of life evaluations every 12 weeks until disease progression and long-term survival follow-up every 6 months after treatment ends.
Tumor assessments every 12 weeks and survival follow-up visits at least every 6 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177Lu-DOTATOC Therapy in Patients With SSTR-Positive Neuroendocrine and Other Related Tumors
Study of Lutetium-177 DOTATATE Dosage Based on Individualized Imaging for Treating Adults with Neuroendocrine Tumors
Safety and Effectiveness of a New 18F Labeled Fibroblast Activation Protein Probe for Early Tumor Detection
Including Lung, Pancreatic, Neuroendocrine, and Thyroid Cancers
Phase III Study of 18F-DOPA PETCT Imaging Optimization Using New Digital Scanner and Furosemide in Pediatric and Adult Patients with Neuroendocrine and Brain Tumors, Parkinsons, and Congenital Hyperinsulinism
Study of 61Cu-NODAGA-LM3 PETCT Compared to 68Ga-DOTATOC for Detecting Neuroendocrine Tumors
A Phase III Randomized, Open-label Single Center Trial
Phase II Study of 68Ga-HA-DOTATATE PETCT Imaging for Patients with Known or Suspected Somatostatin Receptor Positive Tumors including Neuroendocrine Tumors
Evaluating ADCT-701 for Neuroendocrine and Related Tumors A First-in-Human Phase I Study of Intravenous Antibody Drug Conjugate Treatment
Phase II Study of Adjuvant Dendritic Cell Vaccination Using Patients Own Tumor Material After Surgery for Stage IV Rare Cancers including Head and Neck, Neuroendocrine Tumors, and Soft Tissue Sarcoma
Pilot Study Using FDA-Approved Radiotracers in Total-Body PETCT Scanning for Prostate, Breast, and Neuroendocrine Tumors
Phase I Study Evaluating Safety and Effects of BL-M14D1 by Intravenous Infusion in Patients with Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors, and Other Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).